Safety, efficacy and biomarker analysis of deulorlatinib (TGRX-326) in ALK-positive non-small-cell lung cancer: a multicentre, open-label, phase 1/1b trial.
Zhao S, Zhou H, Yang N, Wang Z, Jin W, Ma Y, Xue J, Li X, Liu Y, Meng R, Zhou J, Cheng Y, Wang Y, Yu Z, Cao Y, Zhao Y, Huang Y, Fang W, Zhang Y, Hong S, Wu B, Shi Y, Cao J, Xu M, Zhang X, Hu L, Peng B, Yang Y, Zhang L, Zhao H.
Zhao S, et al. Among authors: yang y.
J Thorac Oncol. 2024 Nov 15:S1556-0864(24)02445-6. doi: 10.1016/j.jtho.2024.11.010. Online ahead of print.
J Thorac Oncol. 2024.
PMID: 39551469